Mebendazole

A new RP-HPLC method for the assay of mebendazole in in unadulterated and in tablet measurements has been developed and validated. The present chromatographic study was carried on μ Bondapak® C18 (250X4.6 mm), 5μm with a flow rate of 1.0mL/min of mobile phase and UV detection at of 218nm and ambient column temperature with mobile phase of NaH2PO4 buffer(pH-5.0) and acetonitrile in the ratio of 65:35%v/v as the mobile phase. The retention time for mebendazole were found to be 2.60mins respectively. The developed RP-HPLC method was validated as per ICH guidelines and was found to be suitable for pharmacokinetic studies.

Mebendazole is a poorly soluble, highly permeable drug and the rate of its oral absorption is often controlled by the dissolution rate in the gastrointestinal. The poor dissolution rate of water-insoluble drugs is still a major problem confronting the pharmaceutical industry. There are several techniques to enhance the dissolution of poorly soluble drugs. Among them, the technique of Liquisolid compacts is a promising technique towards such a novel aim. In this study, the dissolution behaviour of mebendazole from liquisolid compacts was investigated in 0.1 N HCl. Liquisolid compacts were prepared by using PEG 400 as the liquid vehicle or non-volatile solvent. Avicel PH 102 as absorbing carrier and Aerosil 200 as adsorbing coating material. The ratio of carrier to coating powder material were kept different in formulations. The prepared liquisolid compacts were evaluated for their micromeritic properties and possible excipients interactions. The tableting properties were falling within acceptable limits. The in vitro dissolution study confirmed increase in drug release from liquisolid compacts compared to marketed preparation. This was due to an increase in wetting properties and surface of drug available for dissolution.

In the present investigation an attempt has been made to prepare and evaluate medicated lollipop of mebendazole. One of the major health problems faced by hundreds of millions of school-age children is infection by helminths, more commonly known as worms. Mebendazole is used as a broad-spectrum anthelmintic. The conventional dosage forms like tablets, capsules, syrups etc are inconvenient for paediatric patients because of difficult to swallow tablets and capsules or unpleasant taste of drug. As a result, the demand for developing new technologies has been increasing day by day. Lollipops or lozenges are flavored medicated dosage forms intended to be sucked and held in the mouth or pharynx containing one or more medicaments usually in the sweetened base. Medicated lollipop is designed to improve patient compliance, acceptability and increase oral retention time. The lollipops were prepared by heating and congealing method using methylcellulose as polymer. Drug-excipient compatibility study was carried out using FT-IR. All the formulations were subjected to various physicochemical evaluations like weight variation, hardness, drug content, friability etc. The in-vitro dissolution study of F0 was found to be 96.14% at 15min whereas F1 was found to be 99.33% at 25min. Stability study was carried out as per ICH-Guidelines (Q1A) at 30oC and 65% RH. From the present study it can be concluded that addition of hydrophilic polymers yield good result to prolong oral retention time of lollipop. Medicated lollipop can provide an attractive alternative formulation in the treatment of paediatric patients.